Ipamorelin

Ipamorelin is a pentapeptide growth hormone secretagogue notable for its selectivity: unlike earlier secretagogues such as GHRP-6, it causes minimal elevation of cortisol, prolactin or ACTH at effective doses.

Agonism at the GHS-R1a (ghrelin) receptor on pituitary somatotrophs triggers GH release via a pathway distinct from GHRH, which explains why the two classes are often studied in combination. Ipamorelin has no relevant affinity for the receptors that mediate cortisol and prolactin release.

Store the sealed lyophilized vial at 2-8 °C, protected from light; brief exposure to room temperature during shipping is generally tolerated. Refrigerate after reconstitution at 2-8 °C and use within the period supported by stability data for the substance (typically 2-4 weeks). Avoid repeated freeze-thaw cycles: each cycle increases the risk of aggregation and hydrolysis of the peptide bond. Do not shake the vial; swirl gently and direct the liquid stream against the glass wall rather than at the powder cake.

• Sealed lyophilized vial, stored as supplied
• Bacteriostatic water (0.9% benzyl alcohol) for reconstitution
• Insulin syringes (29-31G, 0.5 mL / 100 units)
• Reconstitution syringe (1-3 mL, 21-23G needle)
• 70% isopropyl alcohol swabs
• Sharps container for used needles
• Labels and a logbook for batch, date and volume

Preclinical and early clinical data report dose-dependent GH release with a favorable selectivity profile; a Phase II trial in postoperative ileus did not meet its primary endpoint. Reported effects include transient hunger, lightheadedness and injection-site reaction.

Wash your hands, then disinfect the vial septum and the injection site with 70% isopropyl alcohol and allow both to air dry. Draw up the intended volume, remove air bubbles and pinch a subcutaneous skin fold. Insert at a 45-90° angle depending on fat thickness, aspiration is not required for subcutaneous administration, and inject slowly. Withdraw the needle, apply light pressure and discard the needle in a sharps container. Rotate injection sites systematically (abdominal quadrants, flanks, thighs) to prevent lipohypertrophy and local irritation.

Peptide research protocols are studied against a background of adequate protein intake (approximately 1.6-2.2 g/kg/day in the training literature), consistent sleep of 7-9 hours, and controlled training load. Sleep deprivation and chronic psychological stress both dampen growth hormone pulsatility and disrupt tissue remodeling, complicating the interpretation of any observed effect. Alcohol, smoking and large caloric deficits are likewise documented modifiers of recovery outcomes.

1. Raun K. et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998.
2. Gobburu J.V. et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin. Pharm Res, 1999.
3. Beck D.E. et al. Ipamorelin for postoperative ileus: Phase 2 results. J Gastrointest Surg, 2014.